| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $10,629 | 1 | 33 |
Sells | $15,424 | 2 | 67 |
| Heltzen Michael | Chief Executive Officer | 1 | $10,629 | 0 | $0 | $10,629 |
| Korman Tyler Paz | Chief Scientific Officer | 0 | $0 | 2 | $15,424 | $-15,424 |
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
Over the last 12 months, insiders at eXoZymes, Inc. have bought $10,629 and sold $15,424 worth of eXoZymes, Inc. stock.
On average, over the past 5 years, insiders at eXoZymes, Inc. have bought $10,629 and sold $15,424 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heltzen Michael (Chief Executive Officer) — $10,629.
The last purchase of 1,040 shares for transaction amount of $10,629 was made by Heltzen Michael (Chief Executive Officer) on 2025‑07‑02.
| 2026-04-09 | Sale | Korman Tyler Paz | Chief Scientific Officer | 750 0.0093% | $10.53 | $7,894 | -12.59% | |
| 2026-04-08 | Sale | Korman Tyler Paz | Chief Scientific Officer | 750 0.0089% | $10.04 | $7,530 | -4.50% | |
| 2025-07-02 | Heltzen Michael | Chief Executive Officer | 1,040 0.0129% | $10.22 | $10,629 | +1.67% |
| Increased Positions | 4 | +80% | 7,302 | +12.19% |
| Decreased Positions | 2 | -40% | 4,624 | -7.72% |
| New Positions | <1 | New | 2 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 7 | +40% | 62,601 | +4.47% |